Indivior vs PTC Therapeutics
PTC Therapeutics reported revenue of $1.7 billion in fiscal 2025, 1.4 times Indivior's $1.2 billion in fiscal 2025. Indivior's revenue grew 4.3% in its latest year, and PTC Therapeutics' grew 114.5%. Indivior had an operating margin of 21.1%, against 50.1% at PTC Therapeutics. Free cash flow was −$93 million at Indivior and $702 million at PTC Therapeutics.
Side by side
| Indivior | PTC Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.2B | $1.7B |
| Revenue growth | 4.3% | 114.5% |
| Revenue growth a year, last 5 years | — | 35.4% |
| Gross margin | 80.2% | — |
| Operating margin | 21.1% | 50.1% |
| Net margin | 16.9% | 39.4% |
| Free cash flow | −$93M | $702M |
| Free cash flow margin | −7.5% | 40.6% |
| Return on capital | — | — |
| Net debt to EBITDA | 0.5x | — |
| Dividends and buybacks | $11M | $0M |
| Change in diluted share count | −3.8% | 14.9% |
| Last close | $36.28 | $65.44 |
| P/E at the last close | 10.1× | — |
| Insider trades, last 12 months | bought $229,274, sold $2.8 million | sold $55.5 million |
| Piotroski F-score | 4 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
IndiviorPTC Therapeutics
Operating margin
Percent of revenue
IndiviorPTC Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
IndiviorPTC Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Indivior and PTC Therapeutics pages.